Volume Grew While Pricing Cut the Average Sale
GRAIL's release put total revenue at $37.5 million, up 4% from $36.2 million a year earlier. Galleri screening revenue was $37.3 million, up 14%, on volume of more than 56,000 tests, up about 24%. Year-to-date Galleri volume exceeded 174,000 tests, up 36%. Net loss was $103.6 million, or $2.21 per share. Non-GAAP adjusted EBITDA was a $92.6 million loss, wider than the year-ago $71.7 million loss. Adjusted gross margin fell to 42% from 55%. Cash, cash equivalents and short-term marketable securities totaled $788.7 million at quarter end.
Investing.com said Wall Street had expected about $45.3 million of revenue, a roughly 17% miss. Its follow-up note said promotional pricing lowered the average selling price to about $660 and that TD Cowen and Baird cut price targets after the print. CEO Josh Ofman said in the release that promotional pricing initiatives are gaining traction alongside market education as the company pushes toward broader access.
An FDA Vote That Did Not Carry the Tape
In September the FDA's Molecular and Clinical Genetics Panel of the Medical Device Advisory Committee voted in favor of approval of Galleri. GRAIL said it anticipates an FDA decision by early first quarter 2027. The company also pointed to NHS-Galleri and PATHFINDER 2 publications covering about 175,000 participants. Those are real regulatory and clinical milestones, but Thursday's tape treated the revenue miss and margin compression as the nearer-term catalyst. Investing.com noted GRAIL raised full-year Galleri sales-revenue growth guidance to 17% to 21% and said cash provides runway into 2029, yet that did not stop the gap lower.
Seventeen Percent Inside a Nineteen-Percent Monthly Range
GRAL's nearest post-print monthly on OptionSlam's earnings page is the November 20 expiration. OptionSlam priced that monthly implied move at about 19.08%, with a $140 straddle near $26.60 against a roughly $139.44 reference. That puts break-evens near $112.84 and $166.04.
A $119.50 Public.com premarket print is about $6.66 above the lower break-even, or a 16.8% drop from Wednesday's $143.66 close versus the roughly 19% move the chain priced. At $119.50 the $140 put would hold about $20.50 of intrinsic value against the straddle's roughly $26.60 cost, so a long monthly straddle bought near Wednesday's mids would still be short of covering its premium on intrinsic alone if the stock opened there, while a short straddle would still have cushion pending how fast post-print IV falls. Delayed Cboe quotes are the place to check live November 20 markets. Our implied volatility guide covers post-event IV behavior, and the OCC options disclosure document explains the risks of standardized options.
When the Fundamental Miss Is Large but Still Inside the Premium
A mid-cap biotech with a binary FDA calendar can keep wide straddles even after the earnings event, because the approval decision remains ahead. Traders comparing the realized gap with the November 20 break-evens are separating the earnings reaction from the later regulatory catalyst. The print itself cleared neither the revenue bar nor the margin bar; the options market had simply charged enough for a move of this size that Thursday's premarket level was still inside the prepaid range.
Sources
*By the OptionsPilot Editorial Team. Published November 5, 2026, 7:20 AM PT. This article is for education only and is not investment advice. Options involve risk and are not suitable for all investors.*
